-
公开(公告)号：US20230019032A1
公开(公告)日：2023-01-19
申请号：US17224733
申请日：2021-04-07
发明人： Valerio BERDINI , Ildiko Maria BUCK , James Edward Harvey DAY , Charlotte Mary GRIFFITHS-JONES , Thomas Daniel HEIGHTMAN , Steven HOWARD , Christopher William MURRAY , David NORTON , Marc O'REILLY , Alison Jo-Anne WOOLFORD , Michael Liam COOKE , David COUSIN , Stuart Thomas ONIONS , Jonathan Martin SHANNON , John Paul WATTS
IPC分类号： C07D405/14 , C07D403/14 , C07D409/14 , C07D471/04 , C07D413/14 , C07D471/08 , C07D401/14 , C07D417/14 , A61P35/00 , A61K31/444 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/553 , C07D403/04 , C07D487/04 , C07D497/08 , C07D498/22 , C07D513/04
摘要： The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.
-
公开(公告)号：US20190047990A1
公开(公告)日：2019-02-14
申请号：US15767775
申请日：2016-10-20
发明人： Valerio BERDINI , Ildiko Maria BUCK , James Edward Harvey DAY , Charlotte Mary GRIFFITHS-JONES , Thomas Daniel HEIGHTMAN , Steven HOWARD , Christopher William MURRAY , David NORTON , Marc O'REILLY , Alison Jo-Anne WOOLFORD , Michael Liam COOKE , David COUSIN , Stuart Thomas ONIONS , Jonathan Martin SHANNON , John Paul WATTS
IPC分类号： C07D405/14 , A61P35/00 , A61K31/506 , C07D471/04 , C07D487/04 , A61K31/5377 , A61K31/55 , A61K31/553 , C07D498/22 , C07D497/08 , C07D513/04 , C07D403/04 , C07D403/14 , A61K31/444 , C07D409/14 , A61K31/541
CPC分类号： C07D405/14 , A61K31/444 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/553 , A61P35/00 , C07D401/14 , C07D403/04 , C07D403/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/04 , C07D497/08 , C07D498/22 , C07D513/04
摘要： The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof. The compounds are inhibitors of ERK1/2 kinases and will be useful in the treatment of ERK1/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.
-
搜索结果
2 条记录 (耗时 0.028 秒)
